1. Home
  2. Insights & Perspectives
  3. Interim CEO: Biovend of Early-Stage Tech Company

Interim CEO: Biovend of Early-Stage Tech Company

Biovend develops web enabled secure vending freezers to dispense biological reagents in medical research laboratories

Posted

Biovend Biological Reagents

Jason Bresnehan, an interim CEO with hard-nosed commercial acumen

On behalf of venture capital investor Momentum Ventures Jason Bresnehan was appointed the interim CEO after the departure of the founding CEO.  Biovend develops web enabled secure vending freezers to dispense biological reagents in medical research laboratories.

Jason's role will be to:

  •  Recruit a general manager and engineering team
  • Get the R&D program back track by overcoming the technical difficulties of vending robotics operating in -10 degrees Celsius environment
  • Get the fron end point of use (PoU) software application development back on track
  • Get the back-end SQl based inventory management and ERP system back on track
  • Identify USA based trial customers and negotiate a deployment trial. Target customers include  Amersham Biosciences USA , Applied Biosystems USA , Eppendorf Germany , Fermentas Lithuania , Fisher Scientific USA , Invitrogen USA , New England Biolabs USA , Panvera USA , Perkin Elmer Life Sciences USA , Promega USA , Qiagen USA , Roche Applied Sciences Germany , Sigma Aldrich USA , Takara US
  • Raise bridging finance
  • Raise a Series B venture capital round
  • Develop business plans, marketing plans and investment memorandum
  • Explore new market segments outside of life sciences

Jason was also appointed as Director serving on the Board. Board governance was formal because the Board was made up of Series A and Serie B venture capital investor representatives and an independent. Jason prepared all monthly Board papers with the standard agenda including budget vs actuals, financial performance, cashflow, sales and business development, operations and M&A opportunities.

Biovend Montage
Biovend Montage

About Biovend

  • A startup founded in 1999, and concluded a seed then Series A round in 2000
  • Product is a web enabled robotic vending freezers which dispense biological reagents for use in medical and biological research laboratories
  • Target customers are global life science companies who manufacture biological reagent consumables and sell via an hour based system where laboratory technicians draw from the consumable from an unlocked domestic freezer and write down what they took from the freezer. 
  • Key target customers are in the USA

Looking for highly commercial, cut-to-the-chase Interim CEO who can makes things happen in difficult circumstances. Contact Evahan Managing Director and Principal Consultant Jason Bresnahan to explore how he can assist.

Share this Insight

Latest Insights

Archives